Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy
- PMID: 23076968
- DOI: 10.1161/CIRCULATIONAHA.111.076257
Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy
Abstract
Background: The clinical efficacy of alcohol septal ablation for obstructive hypertrophic cardiomyopathy (HCM) has been demonstrated, but the long-term effects of the procedure remain uncertain. This study examined the survival of patients after septal ablation performed in a tertiary HCM referral center.
Methods and results: We examined 177 patients (mean age, 64 years; 68% women) who underwent septal ablation at our institution. Over a follow-up of 5.7 years, survival free of all mortality was no different than the expected survival for a comparable general population, and similar to that of age- and sex-matched patients who underwent isolated surgical myectomy (8-year survival estimate, 79% versus 79%; P=0.64). For the end point of documented sudden cardiac death or unknown cause of death, the incidence per 100 person-year follow-up was 1.31 (95% confidence interval, 0.60-2.38). Residual left ventricular outflow tract gradient after ablation was an independent predictor of long-term survival free of any death.
Conclusions: In this nonrandomized study of carefully selected patients undergoing septal ablation by experienced operators in a tertiary referral HCM center, long-term survival was favorable and similar to that of an age- and sex-matched general population, and to patients undergoing surgical myectomy, as well, without an increased risk of sudden cardiac death.
Comment in
-
Obstruction in hypertrophic cardiomyopathy: how often does it occur? Should it be treated? If so, how?Circulation. 2012 Nov 13;126(20):2369-70. doi: 10.1161/CIRCULATIONAHA.112.144667. Epub 2012 Oct 17. Circulation. 2012. PMID: 23076969 No abstract available.
Similar articles
-
Predictors of an optimal clinical outcome with alcohol septal ablation for obstructive hypertrophic cardiomyopathy.Catheter Cardiovasc Interv. 2013 Jan 1;81(1):E58-67. doi: 10.1002/ccd.24328. Epub 2012 Apr 17. Catheter Cardiovasc Interv. 2013. PMID: 22511295
-
Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy.J Am Coll Cardiol. 2007 Jan 23;49(3):350-7. doi: 10.1016/j.jacc.2006.08.055. Epub 2007 Jan 4. J Am Coll Cardiol. 2007. PMID: 17239717
-
Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy.Circulation. 2008 Jul 8;118(2):131-9. doi: 10.1161/CIRCULATIONAHA.107.738740. Circulation. 2008. PMID: 18591440
-
Does myectomy convey survival benefit in hypertrophic cardiomyopathy?Heart Fail Clin. 2007 Jul;3(3):275-88. doi: 10.1016/j.hfc.2007.04.010. Heart Fail Clin. 2007. PMID: 17723936 Review.
-
Controversies in cardiovascular medicine. Benefits of surgery in obstructive hypertrophic cardiomyopathy: bring septal myectomy back for European patients.Eur Heart J. 2011 May;32(9):1055-8. doi: 10.1093/eurheartj/ehr006. Epub 2011 Feb 14. Eur Heart J. 2011. PMID: 21324934 Review.
Cited by
-
Modern Perspectives on Hypertrophic Cardiomyopathy-No One Size Fits All.Tex Heart Inst J. 2024 Aug 1;51(2):e248423. doi: 10.14503/THIJ-24-8423. Tex Heart Inst J. 2024. PMID: 39086311 Free PMC article. Review.
-
The Risk of Ventricular Arrhythmias between Alcohol Septal Ablation and Septal Myectomy in Hypertrophic Cardiomyopathy: A Meta-Analysis on Septal Reduction Therapy.Rev Cardiovasc Med. 2022 Nov 30;23(12):391. doi: 10.31083/j.rcm2312391. eCollection 2022 Dec. Rev Cardiovasc Med. 2022. PMID: 39076650 Free PMC article.
-
Myocardial contractility characteristics of hypertrophic cardiomyopathy patients with and without sarcomere mutation.Heart Vessels. 2024 Nov;39(11):939-948. doi: 10.1007/s00380-024-02414-5. Epub 2024 May 28. Heart Vessels. 2024. PMID: 38806839
-
Sex-Related Differences in Patients With Hypertrophic Cardiomyopathy Undergoing Alcohol Septal Ablation.J Am Heart Assoc. 2024 May 7;13(9):e032553. doi: 10.1161/JAHA.123.032553. Epub 2024 May 3. J Am Heart Assoc. 2024. PMID: 38700034 Free PMC article.
-
A systematic review of present and future pharmaco-structural therapies for hypertrophic cardiomyopathy.Clin Cardiol. 2024 Jan;47(1):e24207. doi: 10.1002/clc.24207. Clin Cardiol. 2024. PMID: 38269637 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
